Expert Interview
Discussion of IDO inhibitors from a basic science and research perspective. Specifically discussing potential bioavailability and solubility issues.
Ticker(s): NLNK, BMY, RHHBYNIH research scientist that has the ability to speak to the bioavailability and solubility characteristics of the IDO1 class.
Please explain your background working with IDO inhibitors.
Added By: joemac84What are you impressions of IDO inhibitors currently under development as a pathway and class of therapies?
Added By: joemac84Can you explain how indoximod (wholly owned by Nlnk, data read out at asco June 2016) which has a different MOA than 919 or incy's ido, works? Do you feel that it has a compelling profile?
Added By: user1a9v3vo51. Can you compare the profiles of epacodostst to gdc-0919? I believe their pk profiles are both publicly characterized. Do you see any differences?
2. Do you think Roche / Genentech will take gdc-0919 forward in late stage trials, as Merck /incyte did with EPA?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
